Search

Genfit

Закрыт

СекторЗдравоохранение

11.48 -2.21

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

11.36

Макс.

11.68

Ключевые показатели

By Trading Economics

Доход

-76M

Продажи

32M

Прибыль на акцию

-1.525

Рентабельность продаж

-237.939

Сотрудники

161

EBITDA

-7M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+29.76% upside

Дивиденды

By Acuity

Следующий отчет о доходах

29 сент. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

591M

Предыдущая цена открытия

13.69

Предыдущая цена закрытия

11.48

Genfit График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

20 сент. 2026 г., 04:01 UTC

News

Ethereum is declining, reversing four sessions of gains, with a cumulative return of -2.04% since Saturday amid ongoing geopolitical instability affecting markets.

20 сент. 2026 г., 04:01 UTC

News

Ethereum is declining, reversing four sessions of gains, amid ongoing geopolitical instability related to the Middle East conflict affecting energy prices and markets.

20 сент. 2026 г., 02:51 UTC

News

Bitcoin is modestly lower, continuing a trend since Saturday, as the People's Bank of China maintains its one-year Loan Prime Rate at 3.00%.

20 сент. 2026 г., 02:51 UTC

News

Bitcoin is modestly lower, continuing a trend since Saturday's close, as the People's Bank of China maintains its one-year Loan Prime Rate at 3.00%.

19 сент. 2026 г., 00:06 UTC

News

Hf Foods Group Inc. has terminated its $100 million equity offering program, with the stock declining in after-market trading following this decision.

19 сент. 2026 г., 00:02 UTC

News

Block Inc is facilitating Ideal Nutrition's expansion to at least 20 U.S. locations, contributing to a modest increase in its stock during after-market hours.

19 сент. 2026 г., 00:02 UTC

News
Social Media

MongoDB reported after-market earnings of $771.77 million and EPS of $1.90, exceeding estimates, with stock trading higher in line with market trends.

19 сент. 2026 г., 00:02 UTC

News
Social Media

Accenture PLC and Anthropic announced a partnership to invest $1 billion each in AI safety, driving a significant increase in Accenture's stock price in after-hours trading.

19 сент. 2026 г., 00:02 UTC

News

Shares lower in after-market as DOJ reviews antitrust lawsuit.

19 сент. 2026 г., 00:02 UTC

News
Correlated Moves

Corning Inc's stock is modestly lower in after-market trading, potentially influenced by ASML Holding, despite four consecutive higher daily closes leading into this session.

19 сент. 2026 г., 00:02 UTC

News

Kimberly-Clark Corp is higher in after-market trading following plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns.

19 сент. 2026 г., 00:01 UTC

News

S&P Global Inc is experiencing modest gains in after-market trading, recovering from an early dip while remaining below its 20-day moving average.

19 сент. 2026 г., 00:01 UTC

News

RTX Corp is seeing a modest decline in after-market trading, continuing a downward trend since Friday's close and remaining below its 20-day moving average.

19 сент. 2026 г., 00:01 UTC

News

Union Pacific Corp shares are trading lower in after-market hours, despite UBS upgrading its rating to Buy and raising the price target to $339.

18 сент. 2026 г., 23:41 UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

18 сент. 2026 г., 23:31 UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

18 сент. 2026 г., 23:26 UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

18 сент. 2026 г., 23:16 UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

18 сент. 2026 г., 23:11 UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

18 сент. 2026 г., 23:11 UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

18 сент. 2026 г., 23:06 UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

18 сент. 2026 г., 23:06 UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

18 сент. 2026 г., 23:06 UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

18 сент. 2026 г., 23:06 UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

18 сент. 2026 г., 23:06 UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

18 сент. 2026 г., 23:06 UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

18 сент. 2026 г., 23:06 UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

18 сент. 2026 г., 23:06 UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

18 сент. 2026 г., 23:06 UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

18 сент. 2026 г., 23:01 UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

Сравнение c конкурентами

Изменение цены

Genfit Прогноз

Целевая цена

By TipRanks

29.76% рост

Прогноз на 12 месяцев

Средняя 15 EUR  29.76%

Максимум 15 EUR

Минимум 15 EUR

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для Genfit на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

1 ratings

1

Покупка

0

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.